Skip to main content

Advertisement

We're creating a new version of this page. See preview

  • Research article
  • Open Access
  • Open Peer Review

Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from Rheumatoid arthritis patients

  • 1Email author,
  • 1,
  • 2,
  • 3,
  • 1,
  • 3,
  • 2 and
  • 1
BMC Musculoskeletal Disorders201516:51

https://doi.org/10.1186/s12891-015-0516-3

©  Santos Savio et al.; licensee BioMed Central. 2015

  • Received: 9 January 2015
  • Accepted: 2 March 2015
  • Published:
Open Peer Review reports

Abstract

Background

Pro-inflammatory cytokines are directly implicated in the pathogenesis of Rheumatoid arthritis (RA). Variable clinical response to cytokine targeted therapies as TNFalpha and IL-6, strongly highlights the heterogeneity of inflammatory process in RA. Another cytokine, IL-15 has also been related to the inflammatory process in RA. Recently we described for the first time, the presence of its specific receptor, IL-15Ralpha, in synovial fluid (SF). The aim of this work was to compare the expression profile of IL-15Ralpha, its ligand IL-15, TNFalpha and IL-6 and how these cytokines are correlated in SF from RA patients taking as a reference Osteoarthritis (OA), an articular but not autoinmmune disease.

Methods

Synovial fluids were obtained from the knee joints of 60 patients, 30 with confirmed diagnosis of RA and 30 with OA diagnosis. The levels of TNFalpha, IL-6, IL-15 and IL-15Ralpha were measured by ELISA. A statistical analysis was performed with GraphPad Prism v5.0 using the Mann–Whitney U test and Spearman’s rank correlation. A cluster analysis was run in MeV software v4.9.0 and differences across clusters were evaluated by an ANOVA including post-test analysis.

Results

We found higher and significant levels of TNFalpha, IL-6 and IL-15Ralpha but not of IL-15 in RA compared with the OA group. Additionally, a high inter-individual variability in the levels of these 4 cytokines was observed in RA, although we identified 4 patients’ subgroups by cluster analysis of cytokines concentration in SF. We also found a positive correlation between IL-15Ralpha-IL-6 and IL-15Ralpha-IL-15, but not for other pairs of cytokines in RA. In addition we found correlation between the value of IL-15Ralpha in SF and disease activity score, DAS28.

Conclusions

In our current work we found a high inter-individual variability in the levels of TNFalpha, IL-6, IL-15 and IL-15Ralpha in SF of RA patients and were identified four principal clusters of cytokines concentration in SF, suggesting the importance of identifying disease subset of patients for personalized treatment. Finally, we found a correlation between IL-15Ralpha-IL-6, IL-15Ralpha-IL-15, but we did not find any correlation between other pairs of studied cytokines in SF.

Keywords

  • Cytokines
  • Rheumatoid arthritis
  • Osteoarthritis
  • Synovial fluid

Background

RA is a chronic autoimmune and inflammatory disease affecting synovial tissue in multiple joints. Pro-inflammatory cytokines are directly implicated in the pathogenesis of RA promoting synovial proliferation, hyperplasia and angiogenesis. This perpetuates inflammation, stimulates pannus formation and damage of bone and cartilage [1,2]. The proinflammatory cytokines interleukin 1 (IL1), tumour necrosis factor alpha (TNFalpha), and interleukin 6 (IL6), in particular, have been identified and intra-articular as well as systemic levels of these cytokines may to some extent reflect disease activity [3-6]. Treatment with anti TNF alpha inhibitors has been very effective as a biological therapy [7]. Unfortunately, 40% of RA patients who receive a TNF inhibitor fail to achieve an adequate response [8]. Other biological therapies including Tocilizumab [9,10], rituximab [11] and abatacept [12] have been successful in the treatment of RA, but the variable clinical response to these targeted therapies strongly highlights the heterogeneity of inflammatory process in RA. Another cytokine, IL-15 has also been related to the inflammatory process in RA. IL-15 is a pro-inflammatory cytokine which acts at the innate and acquired immune response [13]. This cytokine recruits circulating memory T cells in the synovial membrane and may up regulate other pro-inflammatory cytokines [14,15]. These events include induction of TNF production through activation of synovial T cell and by macrophages via a cell contact dependent mechanism [16], also the activation of Th17 lymphocytes driving IL17 production [17]. Moreover, soluble IL-15 appears to be an important contributor to osteoclastogenesis promoting bone erosion [18]. IL-15 mediates its biological effects by binding to a high affinity heterotrimeric receptor complex which is comprised of IL-15Ralpha, IL-2/15Rbeta and IL-Rgamma. IL-15Ralpha is a unique high affinity private subunit for IL-15. IL-15Ralpha may be secreted as a functional soluble molecule (s-IL-15Ralpha) and could behave as antagonist or agonist by forming a complex with IL-15 [19-21], also, it has been described that soluble IL-15Ralpha could bind to membrane bound IL-15 to induce a reverse signaling mechanism up-regulating the production of IL-6, IL-8, and TNFalpha by human monocytes and in the cancer cell line PC-3 [22,23]. These antecedents highlight the importance of this receptor in IL-15 biology and trigger previous studies of IL-15Ralpha in synovial fluids, where we have detected increasing levels of this receptor in synovial fluids from RA regards to OA [24]. The aim of this work is to compare the expression profile of IL-15Ralpha, its ligand IL-15 and two validated cytokines targets in RA, TNF alpha and IL-6, in SF from RA regards to Osteoarthritis (OA) patients. In addition, we will assess inter-individual expression of these cytokines and will analyze how this cytokines are correlated.

Methods

Patients and samples

Synovial fluids were obtained from the knee joints of 60 patients, 30 with a confirmed diagnosis of RA based on DAS28 criteria and 30 with a diagnosis of OA. All patients showed inflammation and abundant synovial fluid in the cavities of synovial joints. This study was approved by the Amejeiras Hospital Ethics committee and all patients gave written informed consent. Patient demographics are listed in Table 1. Synovial fluid was directly aspirated from the inflamed joint and collected in tubes, immediately after we added hyaluronidase type IV (H3884, Sigma, USA) at 10 ug/mL to synovial fluid, and mixed by inversion followed by spinning at 1000 g for 10 min within 30 min of sample collection. The acellular portion of synovial fluid (synovial liquid) was stored at −80°C before subsequent analysis.
Table 1

Patient’s data

Patients

RA (n = 30)

OA (n = 30)

Sex (M/F)

6/24

11/19

Age (years)

52 +- 15

62 +- 12

Disease duration (years)

12+- 11

6 +- 10

Rheumatoid factor (+/−)

15/15

–

DAS28

4.27+- 1.23

–

ERS

39 + −26.3

CRP

17.5 + −15.6

DMARD (MTX)

30

–

RA, rheumatoid arthritis; OA Osteoarthritis; DAS28, disease activity score in 28 joints; ERS, erythrocyte sedimentation rate; (CRP) C reactive protein; DMARD, disease-modifying antirheumatic drug; MTX, metotrexate.

Cytokine measurement

Levels of cytokines TNFalpha, IL-6, e IL-15 in SF were measured in duplicate using commercially available ELISA kits purchased from R&D Systems according to the manufacturer’s instructions (Quantikine Human TNF alpha, DTA00C(detection limit was 15.6 pg/mL), Quantikine Human IL-6, D6050 (detection limit was 3.12 pg/mL), Quantikine Human IL-15, D1500 (detection limit was 3.9 pg/mL). IL-15Ralpha was quantified by ELISA as previously described [25]. Briefly, the 96-well microtiter plates (Costar, Corning Inc., NY, USA) were treated with 2% glutaraldehyde solution for 2 h at 37°C. After two washes with water, plates were coated with 10 μg/mL of P8 peptide/well, and the plates were then incubated at 4°C overnight. After three washes with phosphate buffered saline pH 7.4 (PBS) containing 0.05% Tween 20, nonspecific binding sites were blocked by incubation for 1 h at 37°C in PBS containing 1% BSA. The blocking solution was replaced by samples (synovial liquid diluted 2-fold in PBS, containing 0.01% BSA and 0.05% Tween 20 or different concentration of recombinant IL-15Ralpha-Fc (147-IR, R&D) in the same buffer). All the samples were in triplicate. Following incubation at 37°C for 2 h, we did three washes with PBS containing 0.05% Tween 20. IL-15Ralpha was detected with a specific antibody against IL-15Ralpha (AF247, R&D System). The bound IL-15Ralpha was detected with HRP-conjugated goat antihuman IgG (A0170, Sigma, USA) by incubation at 37°C for 1 h, followed by 5 washes with PBS, 0.1% Tween 20. The reaction was visualized by adding the substrate solution (3,3,5,5-tetramethylbenzidine [TMB]), and absorbance at 450 nm was measured with an ELISA plate reader (Biotrak GE, Healthcare, USA). The detection limit was 0.25 nM.

Statistical analysis

Statistical analyses were carried out using GraphPad Prism v5.0 (GraphPad Software, San Diego, CA, USA) software implementation of Mann Whitney U-test and Spearman’s rank correlation. For each RA patient the expression ratio relative to the averaged expression of OA patients was calculated. Hierarchical cluster analysis (HCL) of log2 expression ratios profiles are based on Spearman’s rank correlation and average linkage was performed with MeV analysis software v4.9.0 [26]. Analysis of variance (ANOVA) between clusters was calculated using the Kruskal-Wallis test with Dunn’s post-test analysis. For all analysis, P < 0.05 was taken as significant.

Results

Baseline characteristics of patients

Baseline clinical data of patients are presented in Table 1. RA patients received treatment with oral methotrexate (MTX) and low-dose prednisone. All patients were naive to biological agents. The OA patients were a more heterogeneous group regarding treatment, some received Glucosamine sulfate, some analgesic or physiotherapies. Both groups of patients were heterogeneous in terms of age and disease duration. Regarding sex, there was a higher number of women in the RA group, ratio 4:1 female/male according to what has been reported for this disease.

Comparison of cytokines IL-15Ralpha, IL-15, IL-6, and TNFalpha levels in synovial fluid from RA and OA patients

Quantification by ELISA of cytokines IL-15Ralpha, IL-15, IL-6, and TNFalpha in synovial fluids from the knee joints of 30 RA and 29 OA patients, showed that SF from RA patients contained significantly higher concentrations of IL-15Ralpha (p = 0.03, Figure 1A), TNFalpha (p = 0.002, Figure 1C) and IL-6 (p = 0.001, Figure 1D) than the OA group, but in the case of IL-15 we did not find any significant difference between RA and OA groups (p = 0.29) (Figure 1B).
Figure 1
Figure 1

Measured levels of sIL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluids from RA and OA patients. Cytokine concentration of IL-15Ralpha (A), IL-15 (B), TNFalpha (C) and IL-6 (D) were measured in in duplicate SF samples from RA (n = 30) and OA (n = 30) by ELISA. Box plot represents media ± SD. Differences between two groups were performed by Mann–Whitney U test for nonparametric data.

Cluster analysis of SF from RA patients

Two-dimensional Hierarchical cluster analysis of expression patterns in SF of the four studied cytokines was performed (Figure 2). Four principal clusters of patients were identified and also a high correlation between IL-15Ralpha and IL-6 cytokines. Comparison of the SF cytokine concentrations in each cluster was carried out using the Kruskal-Wallis test with Dunn’s post-test analysis. Cluster 1 includes 7 patients which showed low levels of all cytokines (more significantly IL-6 and IL-15Ralpha) or only high level in one of them; Cluster 2 includes 8 patients expressing significantly high concentration of TNFalpha (C2vs.C3:P < 0.001; C2 vs.C4:P < 0.05) and IL-6 (C2vs.C1:P < 0.001; C2vs.C4:P < 0.01) and most of them express high or mid concentration of IL-15Ralpha and/or IL-15. Cluster 3 includes 12 patients expressing significantly low levels of TNFalpha (C3vs.C2:P < 0.001), significantly high levels of IL-6 (C3vs.C1:P < 0.05) and IL-15Ralpha (C3vs.C1:P < 0.05) and high levels of IL-15. This cluster includes 8 out of 15 patients RF+. Cluster 4 includes 3 patients expressing significantly low levels of TNFalpha (C4vs.C2:P < 0.05) and IL-6 (C4vs.C2:P < 0.01), and positive to IL-15, IL-15Ralpha and RF. Analysis of variance showed significant differences across clusters, which may be indicative of heterogeneity of the inflammation process.
Figure 2
Figure 2

Cluster analysis of cytokines concentration in SF from RA patients. Hierarchical Cluster analysis of cytokines expression profiles obtained for 30 RA patients (Spearman rank correlation and single linkage algorithm). Dendrogram resulting from clustering the RA SFs (rows) identified four principal groups of patients (C1-C4). The most intense red blocks represent highly over-expressed cytokines and most intense green blocks represent the cytokines with greatest degree of under-expression. Black indicates cytokines whose expression is similar in the AR and OA reference samples. At the right side C3A and C3B denote two subclusters of cluster 3 showing different levels of IL-15Ralpha expression. RF+ indicates patients which are positive to Rheumatoid factor.

Correlation studies among all four cytokines in RA

Additionally, we performed correlation analysis among all studied cytokines. In correspondence with our previous report, we found a correlation between IL-15Ralpha and IL-6 (r = 0.4335, p = 0.008, Figure 3A). In current work we also found a correlation between IL-15Ralpha and IL-15 (r = 0.313, p = 0.01, Figure 3B). However, there was no positive correlation between IL-15Ralpha and TNFalpha (r = 0.08, p = 0.32) IL-15 and TNFalpha (r = −0.136, p = 0.23), IL-15 and IL-6 (r = 0.10, p = 0.29) or TNFalpha-IL-6 (r = 0.27, p = 0.07) (Figure 3C-F). Also we did the correlation analysis among values of IL-15Ralpha, DAS28, ERS and CRP for each patient at the moment for taking the sample. As a result we found a correlation between IL-15Ralpha and DAS28, but neither to ESR nor CRP. (Figure 4).
Figure 3
Figure 3

Correlation between cytokines concentration in SF from RA patients. Correlations among concentrations of IL-15Ralpha, IL-15, IL-6 and TNF alpha in SF from RA patients were analyzed using spearman’s rank correlation for all possible combinations. Correlations were significant between IL-6/ IL-15Ralpha (A) and IL-15/Il-15Ralpha (B), but not for IL-15Ralpha/TNFalpha (C), IL-6/TNFalpha (D), TNFalpha/IL-15 (E) or IL-6/IL-15 (F). r (the Spearman correlation coefficient), p (p value, was set at significant at 0.05).

Figure 4
Figure 4

Correlation between IL-15Ralpha in SF from RA patients and ERS, PCR and DAS28. Correlations of IL-15Ralpha concentration and DAS28, CRP and ERS were analyzed using spearman’s rank correlation. Correlations were significant IL-15Ralpha and DAS28 (A), but not for CRP and ERS (B and C).

Discussion

Due to RA is a syndrome comprising different pathogenic subsets, studying cytokine expression profile in inflammatory SF provides a unique opportunity to examine the microenvironment within the inflamed joint. In our current work we assessed expression of IL-15Ralpha, IL-15, IL-6 and TNFalpha in RA compared to OA, a rheumatic non autoimmune disease. Besides, we examined how expression of these cytokines inters individual’s patients.

In correspondence to previous studies, we found high varied levels of TNFalpha and IL-6 in patients with RA which were significant compared to the OA group [27-29]. Presence of soluble IL-15Ralpha has been less studied in RA, but it was previously detected as soluble receptor in serum from mice and humans [30]; recently we detected soluble IL-15Ralpha in SF from RA and OA patients, which was the highest in RA. In current work, we confirmed these results with a higher number of patients. It is important to highlight that the ELISA performed to detect IL-15Ralpha used as a capture a previously described peptide which specifically binds to IL-15Ralpha and displace IL-15/IL-15Ralpha binding in a dose dependent manner [25]. Therefore, we considered that detected IL-15Ralpha could not form complexes with endogenous IL-15.

Taking into account presence of IL-15Ralpha in synovial fluid, we were interested in to know how IL-15Ralpha is correlated to its ligand IL-15 and TNFalpha, an important proinflammatory cytokine validated as a therapeutic target in RA. We considered previous reports showing that IL-15 induces TNFalpha production by synovial cells. Also we measured IL-6 based on our previous report where we found correlation between IL-15Ralpha and L-6.

Regarding IL-15, we did not find significant differences for soluble IL-15 comparing RA and OA groups. Interestingly, we found high levels of IL-15 in 6 patients within OA group which corresponds to patients with early diagnosis of disease. Biological onset of OA is not clearly understood but evidence suggests that progression of cartilage degradation is mediated largely by pro-inflammatory cytokines [31,32]. Recent data suggest that innate immunity may be a driver of the OA process, thus, increased levels of the IL-15 protein are found in the synovial fluid of early knee OA patients when compared to end-stage OA [33]. More recently it was reported that serum IL-15 levels are associated with severity of pain in patients with knee OA; this suggests that IL-15 might play a role in the pathogenesis of early OA [34]. Disease duration was not considered as a variable in our study at the moment of including patients. Actually, in our study 60% of patients (18/29) with OA were 24 or fewer months from diagnosis which could explain the fact that we did not find significant differences in IL-15 between RA and OA groups, conversely as previously reported elsewhere [35,36].

Additionally, we studied the inter-individual cytokine expression in RA patients. A pronounced inter-individual diversity of expression patterns for these 4 cytokines was observed in SF. This finding corresponds to previously reported results of heterogeneity obtained when IL-6, TNF alpha, IL-1alpha and IL-1beta which were determined by immunohistochemistry in synovial tissue of RA patients [37]. In current work, we identified 4 clusters of SFs corresponding to different patterns of concentration of these cytokines. Cluster 1 groups 7 patients with low levels of cytokines concentrations. Cluster 2 group patients with at least 3 increased cytokines, high levels of TNFalpha and IL-6 were observed in all patients included in this cluster. Additionally IL-15 or IL-15Ralpha was elevated, suggesting a high inflammation level. Cluster 3 includes patients negative to TNFalpha with high levels of IL-6 which could have high or mid levels of IL-15Ralpha and IL-15. Cluster 4 include patients with high or mid levels of IL-15 and IL-15Ralpha which are negative to IL-6 and TNF alpha, suggesting that the IL-15 system could play an important role in the inflammatory process in these patients, independent of IL-6 or TNFalpha.

Indeed, we found a correlation between IL-15Ralpha and DAS28 suggesting a relation between IL-15Ralpha level and disease activity. Other finding was that 11 of 15 patients positive RF are included in clusters 3 and 4. It is in agreement with a previous report of association between IL-15 and RF. So far, it has not been reported any association between IL-15Ralpha and RF.

Regarding disease duration, we could stratify patients into 2 groups being 1st group (n = 9) those with early disease (we consider early disease patients with <2 years from time of diagnosis); the 2nd group (n = 13) comprises those patients > 10 years from time of diagnosis. Both groups were statistically analyzed and no differences were found. There was none association between disease duration and IL-15Ralpha. Interestingly, we found that in C3B, one of the two subgroups of cluster 3 and including patients with high level of IL-15Ralpha, 83% of them had late disease.

Heterogeneity observed in the expression pattern of the studied cytokines should be taken into account when cytokines are used as targets in a therapeutic approach. In our current study, Cluster 3 and Cluster 4, which include 15 of 30 patients with signs of inflammation, are negative to TNFalpha. This could explain the fact that even when inhibiting TNFα in patients with active RA which results in a rapid and sustained improvement of their signs and symptoms of disease, it has been reported that more than 40% of them do not respond to this treatment [38]. In patients treated with Tocilizumab a humanized monoclonal antibody against IL-6 receptor, also has been reported about 40% of inadequate response [39]. Previous studies have shown a positive correlation between TNFalpha levels in serum and response to therapies inhibiting TNFalpha, although there are reports with the opposite result [40-42]. Frequently, cytokine levels in serum do not correspond with cytokine levels present in synovial fluid.

Cluster analysis has also shown a positive correlation between IL-15Ralpha and IL-6. Additionally we performed correlation analysis between the four studied cytokines. Correlation between IL-15Ralpha and IL-6 was confirmed and interestingly, we found also correlation between IL-15Ralpha and IL-15, which could be indicative of IL-15/IL-15Ralpha complexes detected by ELISA However, we did not find any correlation between IL-15 and IL-6 which suggested a mechanism of IL-6 induction by IL-15Ralpha independently of soluble IL-15. Also IL-15 and TNFalpha were none correlated, probably because induction of TNFalpha by IL-15 takes place in the microenvironment of target cells depending on cell contact and it is not reflected in acellular synovial fluid. In our experiments, we found a well-defined group of patients being negative to TNFalpha; however these patients express high or medium levels of IL-15, only 3 patients showed both TNF alpha and IL-15 high. We did not find any correlation between other pairs of cytokines in this work (IL-15Ralpha/TNFalpha and TNFalpha/IL-6). Therefore, these results reinforce our suggestion that IL-15 reverse signaling through membrane IL-15, could take place in RA synovium as other inducing pathway of IL-6 [24]. Nevertheless, it is important to take into account complexities of the IL-15/IL-15R system, three different functional forms of IL-15 have been identified: 1) the soluble cytokine, 2) IL-15R-independent membrane-bound IL-15 and 3) membrane-anchored IL-15 through IL-15Rα [13,20,23]. Also, IL-15Rα may be secreted as a functional soluble molecule (s-IL-15Rα) and could form a complex with IL-15 [19,21]. Thus, these results raise another question about the role of different presentation forms and complexities of cytokines/cytokines receptor system highlighting the need of personalized medicine in treatment using the cytokines as a target.

Conclusions

In our current work, we found higher levels of TNFalpha, IL-6 and IL-15Ralpha in RA than OA, but not of IL-15 suggesting that IL-15 could be implicated in the OA pathology. Also, our results confirm heterogeneity of the inflammatory process assessed in RA patients where high inter-individual diversity expression patterns of IL-15Ralpha, IL-15, IL-6 and TNFalpha were observed. Despite this, we have identified 4 main clusters of concentration of these cytokines in SF suggesting the importance of identifying disease subgroups to personalize treatment. Finally, we found correlations between IL-15Ralpha-IL-6 and IL-15Ralpha-IL-15, but we did not find any correlation between other pairs of studied cytokines, highlighting a role for IL-15Ralpha in the RA pathology.

Abbreviations

IL-6: 

Interleukin- 6

IL-15: 

Interleukin-15

IL-15Ralpha: 

Interleukin 15receptor alpha

TNFalpha: 

Tumor necrosis factor alpha

IL-2: 

Interleukin-2

IL-1: 

Interleukin-1

RA: 

Rheumatoid arthritis

OA: 

Osteoarthritis

SF: 

Synovial fluid

DAS28: 

Disease Activity Score 28

ELISA: 

Enzyme-linked immunosorbent assay

ANOVA: 

Analysis of Variance

BSA: 

Bovine serum albumin

PBS: 

Phosphate buffered saline

MTX: 

Methotrexate

Declarations

Acknowledgment

The authors thank Jenny Slattery for linguistic advice.

Authors’ Affiliations

(1)
Pharmaceutical Division, Center for Genetic Engineering and Biotechnology, Havana, CP 10600, Cuba
(2)
Rheumatology Department, H. Ameijeiras Hospital, San Lazaro 701, Havana, Cuba
(3)
Bioinformatics Department, Center for Genetic Engineering and Biotechnology, Havana, CP 10600, Cuba

References

  1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.View ArticlePubMedGoogle Scholar
  2. Mcinnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42.View ArticlePubMedGoogle Scholar
  3. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis and osteoarthritis. Lancet. 1988;ii:706–9.View ArticleGoogle Scholar
  4. Arvidsson NG, Gudbjörnsson B, Elfman L, Ryden AC, Tötterman T, Hällgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis. 1994;53:521–4.View ArticleGoogle Scholar
  5. Westacott CL, Whicher JT, Barnes IC, Thompson D, Swan AJ, Diepppe PA. Synovial fluid concentrations of five different cytokines in rheumatic diseases. Ann Rheum Dis. 1990;49:676–81.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis. 1990;49:665–7.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Hochberg MC, Tracey JK, Hawkins-Holts M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(Suppl):ii13–6.PubMedPubMed CentralGoogle Scholar
  8. Navarro-Millán I, Singh J, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012;34:788–802. e3.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11 Suppl 1:S1.View ArticlePubMedGoogle Scholar
  10. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–97.View ArticlePubMedGoogle Scholar
  11. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–806.View ArticlePubMedGoogle Scholar
  12. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–23.View ArticlePubMedGoogle Scholar
  13. McInnes IB, Al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med. 1996;2:175–82.View ArticlePubMedGoogle Scholar
  14. Rückert R, Brandt K, Ernst M, Marienfeld K, Csernok E, Metzler C, et al. Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis? Immunology. 2009;126:63–73.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. Il-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol. 2003;170:2106–12.View ArticlePubMedGoogle Scholar
  16. Mcinnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med. 1997;3:189–95.View ArticlePubMedGoogle Scholar
  17. Yoshihara K, Yamada H, Hori A, Yajima T, Kubo C, Yoshikai Y. IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol. 2007;37:2744–52.View ArticlePubMedGoogle Scholar
  18. Miranda-Carus ME, Benito-Miguel M, Balsa A, Cobo-Ibáñez T, Pérez de Ayala C, Pascual-Salcedo D, et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum. 2006;54:1151–64.View ArticlePubMedGoogle Scholar
  19. Mortier E, Bernard J, Plet AY, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor α- chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol. 2004;173:1681–8.View ArticlePubMedGoogle Scholar
  20. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002;17:537–47.View ArticlePubMedGoogle Scholar
  21. Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, et al. Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ: hyperagonist IL-15•IL-15Rα fusion proteins. J Biol Chem. 2006;281:1612–9.View ArticlePubMedGoogle Scholar
  22. Budagian V, Bulanova E, Orinska Z, Pohl T, Borden EC, Silverman R, et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem. 2004;279:42192–201.View ArticlePubMedGoogle Scholar
  23. Neely GG, Epelman S, Ma LL, Colarusso P, Howlett CJ, Amankwah EK, et al. Monocyte surfacebound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol. 2004;172:4225–34.View ArticlePubMedGoogle Scholar
  24. Machado AC, Chico A, Arrieta CA, Rodríguez Y, García del Barco D, Estévez del Toro M, et al. Proinflammatory soluble interleukin-15 receptor alpha is increased in rheumatoid arthritis. Arthritis. 2012;2012:943156.Google Scholar
  25. Santos A, Cabrales A, Reyes O, Gerónimo H, Rodríguez Y, Garay H, et al. Identification of an interleukin-15 antagonist peptide that binds to IL-15Ra. Biotecnol Apl. 2008;25:320–4.Google Scholar
  26. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34:374–8.PubMedGoogle Scholar
  27. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology. 1999;38:202–13.View ArticlePubMedGoogle Scholar
  28. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997;40:1096–105.View ArticlePubMedGoogle Scholar
  29. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluid from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88–95.View ArticlePubMedGoogle Scholar
  30. Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. Blood. 2012;120:e1–8.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33–42.View ArticlePubMedGoogle Scholar
  32. Sellam J, Berenbaum F. Clinical features of osteoarthritis. In: Firestein GS, editor. Kelley’s Textbook of Rheumatology, vol. 1. 8th ed. Philadelphia: Saunders/Elsevier; 2008. p. 1547–60.Google Scholar
  33. Scanzello CR, Umoh E, Pessler F, Diaz-Torne C, Miles T, Dicarlo E, et al. Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthritis Cartilage. 2009;17:1040e8.View ArticleGoogle Scholar
  34. Sun JM, Sun LZ, Liu J, Su B, Shi L. Serum interleukin-15 levels are associated with severity of pain in patients with knee osteoarthritis. Dis Markers. 2013;35:203–6.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Thurkow EW, van der Heijden IM, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol. 1997;181:444–50.View ArticlePubMedGoogle Scholar
  36. Ortiz AM, Laffon EA, Gonzalez-Alvaro I. CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies. Rheumatol Int. 2002;21:182–8.View ArticlePubMedGoogle Scholar
  37. Ulfgren AK, Gröndal L, Lindblad S, Khademi M, Johnell O, Klareskog L, et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis. 2000;59:439–47.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819–36.View ArticlePubMedGoogle Scholar
  39. Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology. 2014;53:76–84.View ArticlePubMedGoogle Scholar
  40. Mussi A, Bonifati C, Carducci M, D’Agosto G, Pimpinelli F, D’Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11:115–8.PubMedGoogle Scholar
  41. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis. 2008;67:1139–44.View ArticlePubMedGoogle Scholar
  42. Buch MH, Reece RJ, Quinn MA, English A, Cunnane G, Henshaw K, et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology. 2008;47:1469–75.View ArticlePubMedGoogle Scholar

Copyright

© Santos Savio et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us